NCT03472027View on ClinicalTrials.gov

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

September 11, 2018

Study Completion Date

December 4, 2018

Conditions
Melanoma
Interventions
BIOLOGICAL

BCD-145

Anti-CTLA-4 monoclonal antibody, IV infusion

Trial Locations (4)

115478

N.N. Blokhin National Medical Research Center of Oncology, Moscow

190013

"JSC Modern Medical Technologies", Saint Petersburg

197758

N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg

Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT03472027 - Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma | Biotech Hunter | Biotech Hunter